Vyvanse Bed denied for missing prior authorization by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for vyvanse bed are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Requires Prior Authorization for Vyvanse in BED

Blue Cross Blue Shield places prior authorization requirements on Vyvanse for binge eating disorder as a utilization-management tool — the plan wants to confirm clinical appropriateness, severity, and prior-treatment history before approving coverage. A denial for "prior authorization required" most often means either that no PA was submitted before the prescription was filled, or that a PA was submitted but denied because it did not include sufficient clinical documentation. The path forward depends on which situation applies.

## Why This Denial Is Appealable

If the PA was denied on clinical grounds, you have full appeal rights under both the plan's internal process and federal external-review rules. Prior-authorization denials for medications with a specific FDA indication — as Vyvanse has for moderate-to-severe BED — are routinely overturned when the prescriber submits complete documentation mapped against every PA criterion. If the denial was purely administrative (no PA filed), a retrospective PA or an appeal on medical-necessity grounds may still recover coverage depending on your plan's terms.

## Federal Appeal Framework

• Internal appeal — file within the deadline stated on your denial notice (commonly 180 days from receipt).
• Expedited internal appeal — if your condition is urgent, request expedited review; decisions are typically required within 72 hours.
• External review (ACA §2719) — after a final internal denial on a fully-insured BCBS plan, you have approximately four months to request independent external review by an accredited organization.
• ERISA §503 — self-funded employer plans must conduct a full-and-fair review; the plan must provide specific written criteria and explain exactly what documentation was missing or insufficient.
• Concurrent expedited external review — in urgent situations, you may be able to request external review at the same time as the internal appeal.

## Documentation to Gather

1. BED diagnosis confirmation — DSM-5-based documentation of moderate-to-severe BED, signed and dated by the treating clinician. 2. Severity and functional-impairment records — chart notes describing symptom frequency, duration, and impact. 3. Prior-treatment history — documented attempts at behavioral interventions, dietary counseling, and any prior pharmacotherapy, with dates, agents, and outcomes. 4. Prescriber medical-necessity letter — a detailed letter addressing each of BCBS's PA criteria by name, confirming the patient meets every stated requirement. 5. FDA prescribing label — to confirm the labeled indication and reinforce that this is an approved use.

## Criteria-Mapping Structure

Request a copy of BCBS's prior-authorization criteria for Vyvanse in BED (available via your plan's provider portal or member services). List every criterion verbatim. For each, identify the specific chart document that satisfies it. Criteria commonly include: confirmed DSM-5 diagnosis at a specified severity level, documented prior treatment attempts, and prescriber attestation of medical necessity. Filling every gap identified by the PA reviewer — rather than resubmitting the same package — is the most efficient path to approval.